- Home
- UPXI vs IMA Comparison
UPXI vs IMA Comparison
Compare UPXI & IMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$1.10
N/A
Current Price
$5.96
Company Overview
Basic Information| Metric | UPXI | IMA |
|---|---|---|
| Founded | 2018 | 2019 |
| Country | United States | United States |
| Employees | N/A | 15 |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.6M | 65.3M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | UPXI | IMA |
|---|---|---|
| Price | $1.10 | $5.96 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 1 | 2 |
| Target Price | $2.00 | ★ $16.00 |
| AVG Volume (30 Days) | ★ 5.6M | 29.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 92.49 | N/A |
| EPS | ★ 0.76 | N/A |
| Revenue | ★ $15,811,345.00 | N/A |
| Revenue This Year | $118.99 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $1.22 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.54 | $5.70 |
| 52 Week High | $22.53 | $17.50 |
Technical Indicators
Market Signals| Indicator | UPXI | IMA |
|---|---|---|
| Relative Strength Index (RSI) | 52.04 | 36.74 |
| Support Level | $0.54 | N/A |
| Resistance Level | $1.17 | $7.17 |
| Average True Range (ATR) | 0.15 | 0.33 |
| MACD | 0.08 | -0.04 |
| Stochastic Oscillator | 80.71 | 7.89 |
Price Performance
Historical Comparison UPXI
IMA
About UPXI Upexi Inc.
Upexi Inc specializes in the development, manufacturing, and distribution of consumer products with diversification into the cryptocurrency space via Solana. Geographically, the company generates the majority of its revenue from the United States.
About IMA ImageneBio Inc.
ImageneBio Inc is a clinical-stage biopharmaceutical company that develops differentiated therapies for immunological and inflammatory (I&I) diseases. The company is focused on developing IMG-007, a non-depleting anti-OX40 monoclonal antibody, for the treatment of atopic dermatitis.